Septerna (NASDAQ:SEPN) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Septerna (NASDAQ:SEPN) from a hold rating to a sell rating in a report published on Saturday morning.

A number of other research firms also recently issued reports on SEPN. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Septerna in a report on Friday, September 5th. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Septerna in a research report on Thursday, August 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.75.

Septerna Stock Down 1.5%

Shares of SEPN stock traded down $0.29 during trading on Friday, hitting $18.51. The company had a trading volume of 182,158 shares, compared to its average volume of 292,554. The stock’s 50-day moving average is $18.71 and its two-hundred day moving average is $13.35. The stock has a market capitalization of $825.18 million and a price-to-earnings ratio of -1.83. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $22.50 million. On average, research analysts predict that Septerna will post -7.11 EPS for the current fiscal year.

Institutional Trading of Septerna

Several hedge funds have recently added to or reduced their stakes in SEPN. Nuveen LLC purchased a new stake in Septerna in the first quarter worth $139,000. Checkpoint Capital L.P. purchased a new stake in shares of Septerna in the first quarter worth $4,776,000. ADAR1 Capital Management LLC bought a new stake in Septerna during the 1st quarter valued at about $4,174,000. BVF Inc. IL raised its holdings in Septerna by 79.3% in the 1st quarter. BVF Inc. IL now owns 4,396,124 shares of the company’s stock worth $25,454,000 after acquiring an additional 1,944,100 shares during the last quarter. Finally, Swiss National Bank bought a new position in shares of Septerna during the first quarter valued at $174,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.